ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)

Divestiture to Incyte Strengthens Financial Position ARIAD Receives $140 Million Upfront Payment, $135 million to be Received in Potential Oncology Milestones, Tiered Royalty Payments of Between 32% and 50% CAMBRIDGE, Mass.--(Healthcare Sales & Mark... Biopharmaceuticals, Oncology, Licensing, AcquisitionsARIAD Pharmaceuticals, Incyte, Iclusig, ponatinib, chronic myeloid leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news